🔗 Share this article

Chancellor Rachel Reeves has announced she is planning "focused steps to deal with cost of living issues" in next month's financial statement.

In comments to media outlets, she emphasized that lowering inflation is a shared task of both the government and the central bank.

The UK's price growth is forecast to be the most elevated among the G7 industrialized countries this year and the following year.

Possible Energy Bill Interventions

Reports indicate the administration could take action to reduce utility costs, for instance by cutting the present 5% level of VAT charged on energy.

Another approach is to cut some of the policy costs presently included in household expenses.

Fiscal Limitations and Analyst Predictions

The government will obtain the latest assessment from the independent fiscal watchdog, the OBR, on the start of the week, which will clarify how much scope there is for these measures.

The consensus from the majority of analysts is that the Chancellor will have to announce higher taxes or expenditure reductions in order to fulfill her declared fiscal targets.

Earlier on the same day, calculations showed there was a £22bn gap for the chancellor to fill, which is at the more modest range of expectations.

"It is a collective responsibility between the central bank and the administration to continue tackling some of the causes of price increases," Reeves told the BBC in the US capital, at the yearly gatherings of the International Monetary Fund and global financial institution.

Revenue Commitments and Global Concerns

While a great deal of the attention has been on expected tax rises, the chancellor said the most recent figures from the OBR had not changed her vow to election pledges not to raise tax levels on income tax, sales tax or National Insurance.

She attributed an "uncertain world" with rising international and commercial concerns for the Budget tax moves, probably to be focused on those "with the broadest shoulders."

Global Trade Tensions

Commenting on concerns about the United Kingdom's trade ties with the Asian nation she said: "The UK's security interests always are paramount."

Recent declaration by Chinese authorities to increase export controls on critical minerals and other resources that are crucial for advanced tech production led US President Donald Trump to threaten an additional 100% tariff on goods from China, increasing the prospect of an full-scale commercial conflict between the two largest economies.

The American finance chief labeled China's action "commercial pressure" and "a global supply chain control attempt."

Asked about considering the US offer to join its dispute with the Asian nation, the Chancellor said she was "deeply worried" by Chinese measures and encouraged the Beijing authorities "not to put up barriers and restrict access."

She said the decision was "harmful for the international commerce and causes additional headwinds."

"In my view there are fields where we must address Chinese policies, but there are also important chances to sell into Chinese markets, including banking sector and other sectors of the economic system. We've got to get that balance correct."

The Treasury chief also affirmed she was cooperating with G7 counterparts "on our own critical minerals plan, so that we are more independent."

NHS Drug Pricing and Funding

Reeves also admitted that the price the NHS pays for pharmaceuticals could rise as a result of ongoing negotiations with the US government and its pharmaceutical firms, in return for reduced taxes and investment.

Some of the biggest global pharmaceutical manufacturers have said in recent statements that they are either halting or canceling operations in the United Kingdom, with several attributing the low prices they are receiving.

Last month, the government science advisor said the price the health service spends on medicines would need to increase to prevent companies and drug research funding leaving the UK.

Reeves stated to media: "We have seen due to the payment system, that drug testing, innovative medicines have not been offered in the United Kingdom in the way that they are in other EU nations."

"The objective is to ensure that individuals getting care from the NHS are able to access the best critical drugs in the globe. And so we are reviewing these issues, and... aiming to secure increased investment into the UK."